Publication at First Faculty of Medicine |
2018
Abstract
The prevalance of heart failure with reduced ejection fraction (HFrEF) is growing as the cost of improved coronary artery diseas therapy. Disease-modifying drugs include: ACE-inhibitors, ATII-blockers, mineralocorticoid receptor antagonists, ivabradin and sacubitril/valsartan.
These drugs significantly improve not only quality of life, but also life expectations. However, sometimes they are prescribed inaccordingly and these drugs could also have significant adverse effects.
This manuscript reviews the most frequent pitfalls in HFrEF medication.